FDA Approves Inotuzumab for Adults with B-Cell Acute Lymphoblastic Leukemia

FDA has approved inotuzumab (Besponsa®) for some adults with B-cell acute lymphoblastic leukemia (ALL). The approval covers patients with B-cell ALL whose disease has relapsed or is refractory to standard chemotherapy.

Cancer Currents: An NCI Cancer Research Blog